Streetinsider.com Pre-Open Movers 07/08: (INO) (LINE) (DELL) Higher; (CYTK) (BABY) (NDLS) Lower (more...)

Inovio Pharmaceuticals, Inc. (NYSE: INO) 13% HIGHER; announced today that in a preclinical study of its influenza DNA vaccine against the virulent, newly emergent H7N9 flu virus, 100% of the vaccinated animals were protected against sickness and death when they were challenged with a lethal dose of H7N9 virus. The results from a study in mice demonstrated that Inovio's vaccine generated not only hemagglutination inhibition (HAI)-based protection against the H7N9 virus but also strong T-cell responses. Inovio's DNA vaccine created cellular immune responses that could reduce the severity of the infection in a person that acquires the virus and limit the spread of the virus in a pandemic setting. Detailed study results will be presented at an invited plenary session at the TEPIK/APACI International Influenza Symposium being held in Seoul, South Korea, on July 12, 2013.

Cytokinetics, (Nasdaq: CYTK) 9.9% LOWER; announced an update on the conduct of BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). BENEFIT-ALS is a Phase IIb, multinational, double-blind, randomized, placebo-controlled clinical trial designed to evaluate the safety, tolerability and potential efficacy of tirasemtiv, a fast skeletal muscle troponin activator, in patients with amyotrophic lateral sclerosis (ALS).

Natus Medical, Inc. (NASDAQ: BABY) 9.1% LOWER; sees revenue for the second quarter of 2013 is expected to be between $81 million and $82 million versus previous guidance of $86 million to $90 million. The Wall Street consensus is $88.6 million.

LINN Energy (NASDAQ: LINE) 4.3% HIGHER; BofA/Merrill Lynch upgraded from Neutral to Buy

BreitBurn Energy Partners (NASDAQ: BBEP) 4.2% HIGHER; Baird upgraded from Neutral to Outperform

Linn Co, LLC (NASDAQ: LNCO) 3.8% HIGHER; BofA/Merrill Lynch upgrades from Neutral to Buy

Noodles & Co. (NASDAQ: NDLS) 3.4% LOWER; Wedbush initiated coverage on with a Neutral rating and a price target of $35.00. Analyst Nick Setyan thinks the stock's massive premium is unwarranted. Also, cautious Barron's article over the weekend.

Dell, Inc. (Nasdaq: DELL) 2.7% HIGHER; ISS backs leveraged buyout of by Micheal Dell, Silver Lake.

priceline.com (NASDAQ: PCLN) 2.3% HIGHER; Morgan Stanley upgraded priceline.com from Equalweight to Overweight.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Intra-Cellular Therapies (ITCI) Prices Public Offering of Common Stock
• Interactive Brokers Group (IBKR) PT Raised to $152 at BofA Securities
• California Resources (CRC) PT Raised to $57 at BofA Securities